| Employment |
| No Relationships to Disclose |
|
|
| Leadership |
| Company: ION Pharma |
| Recipient: You |
|
| Stock and Other Ownership Interests |
| No Relationships to Disclose |
|
|
| Honoraria |
| No Relationships to Disclose |
|
|
| Consulting or Advisory Role |
| Company: Daiichi Sankyo/UCB Japan |
| Recipient: You |
| Company: Kura Oncology |
| Recipient: You |
| Company: Accutar Biotech |
| Recipient: You |
| Company: Mitsubishi Tanabe Pharma |
| Recipient: You |
| Company: shivanka Research |
| Recipient: You |
| Company: Johnson & Johnson/Janssen |
| Recipient: You |
|
| Speakers' Bureau |
| No Relationships to Disclose |
|
|
| Research Funding |
| Company: Agenus |
| Recipient: Your Institution |
| Company: Boehringer Ingelheim |
| Recipient: Your Institution |
| Company: Cyteir Therapeutics |
| Recipient: Your Institution |
| Company: Daiichi Sankyo |
| Recipient: Your Institution |
| Company: Genentech/Roche |
| Recipient: Your Institution |
| Company: Janssen |
| Recipient: Your Institution |
| Company: Loxo |
| Recipient: Your Institution |
| Company: Macrogenics |
| Recipient: Your Institution |
| Company: Merck |
| Recipient: Your Institution |
| Company: Moderna Therapeutics |
| Recipient: Your Institution |
| Company: Pfizer |
| Recipient: Your Institution |
| Company: Prelude Therapeutics |
| Recipient: Your Institution |
| Company: Seven and Eight Biopharmaceuticals |
| Recipient: Your Institution |
| Company: Syndax |
| Recipient: Your Institution |
| Company: Artios |
| Recipient: Your Institution |
| Company: Novartis |
| Recipient: Your Institution |
| Company: nurix |
| Recipient: Your Institution |
| Company: TeneoBio |
| Recipient: Your Institution |
| Company: Zymeworks |
| Recipient: Your Institution |
| Company: Olema |
| Recipient: Your Institution |
| Company: Adagene |
| Recipient: Your Institution |
| Company: Astellas |
| Recipient: Your Institution |
| Company: Accutar Biotech |
| Recipient: Your Institution |
| Company: Compugen |
| Recipient: Your Institution |
| Company: Immunogen |
| Recipient: Your Institution |
| Company: Blueprint Pharmaceuticals |
| Recipient: Your Institution |
| Company: Cullinan Oncology |
| Recipient: Your Institution |
| Company: Immune-Onc Therapeutics |
| Recipient: Your Institution |
| Company: Immunitas |
| Recipient: Your Institution |
| Company: Ribon Therapeutics |
| Recipient: Your Institution |
| Company: Step Pharma |
| Recipient: Your Institution |
| Company: Bristol-Myers Squibb/Celgene |
| Recipient: Your Institution |
| Company: Kineta |
| Recipient: Your Institution |
| Company: Hotspot Therapeutics |
| Recipient: Your Institution |
| Company: Conjupro Biotherapeutics |
| Recipient: Your Institution |
| Company: Allorion Therapeutics |
| Recipient: Your Institution |
| Company: Vividion Therapeutics |
| Recipient: Your Institution |
| Company: Georgiamune |
| Recipient: Your Institution |
| Company: Kura Oncology |
| Recipient: Your Institution |
| Company: AstraZeneca |
| Recipient: Your Institution |
| Company: Zai Lab |
| Recipient: Your Institution |
| Company: Abbvie |
| Recipient: Your Institution |
| Company: Avenzo |
| Recipient: Your Institution |
| Company: D3 Bio |
| Recipient: Your Institution |
| Company: OnCusp Therapeutics |
| Recipient: Your Institution |
| Company: Apollo |
| Recipient: Your Institution |
| Company: Medlink |
| Recipient: Your Institution |
| Company: BioNTech SE |
| Recipient: Your Institution |
| Company: Abdera Thereapeutics |
| Recipient: Your Institution |
| Company: Lilly |
| Recipient: Your Institution |
| Company: Sutro Biopharma |
| Recipient: Your Institution |
| Company: Systimmune |
| Recipient: Your Institution |
| Company: Incyte |
| Recipient: Your Institution |
|
| Patents, Royalties, Other Intellectual Property |
| No Relationships to Disclose |
|
|
| Expert Testimony |
| No Relationships to Disclose |
|
|
| Travel, Accommodations, Expenses |
| No Relationships to Disclose |
|
|
| Other Relationship |
| No Relationships to Disclose |
|
|
| (OPTIONAL) Uncompensated Relationships |
| No Relationships to Disclose |
|
|
| (OPTIONAL) Open Payments Link |
| No Relationships to Disclose |
|
|